Leef Brands (LEEEF) Income towards Parent Company (2025 - 2026)
Leef Brands (LEEEF) reported Income towards Parent Company of -$426253.0 for Q1 2026, down 260.38% on a YoY basis from $265776.0 in Q1 2025, and down 260.38% sequentially from $265776.0 in Q1 2025.
Leef Brands (LEEEF) Income towards Parent Company (2025 - 2026) Analysis & Trends
Leef Brands (LEEEF) has 2 years of Income towards Parent Company data on file, last reported at -$426253.0 in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 260.38% year-over-year to -$426253.0; the trailing twelve-month figure through Mar 2026 stood at -$160477.0 (changed N/A YoY), and the FY2025 full-year result was -$17.6 million, up 28.77% from the prior year.
- Income towards Parent Company fell to -$426253.0 in Q1 2026, from $265776.0 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $265776.0 in Q1 2025 to a low of -$426253.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - |
| 7 | Viatris | 20.23 Bn | 18.42 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Leef Brands | 49.91 Mn | 44.15 Mn | 4.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -426,253.00 |
| Mar 31, 2025 | 265,776.00 |